Future Pharmacology最新文献_第4页

Fundamental Considerations of Targeted Drug Therapies for Breast Cancer 乳腺癌靶向药物治疗的基本考虑

Future Pharmacology Pub Date : 2023-10-08 DOI: 10.3390/futurepharmacol3040043

Ileana Castillo-Tobías, Lia Berlanga, Joan Poblano, María del C. Rodríguez-Salazar, Hilda Aguayo-Morales, Luis E. Cobos-Puc

{"title":"Fundamental Considerations of Targeted Drug Therapies for Breast Cancer","authors":"Ileana Castillo-Tobías, Lia Berlanga, Joan Poblano, María del C. Rodríguez-Salazar, Hilda Aguayo-Morales, Luis E. Cobos-Puc","doi":"10.3390/futurepharmacol3040043","DOIUrl":"https://doi.org/10.3390/futurepharmacol3040043","url":null,"abstract":"Breast cancer is a complex disease for which pharmacological treatment does not guarantee success or cure. In addition, current pharmacological therapies induce unwanted side effects due to their lack of specificity or selectivity. Therefore, it is necessary to develop new therapeutic options to improve these aspects. Currently, phytochemicals with antineoplastic properties have been identified from a wide variety of plant sources, and new therapeutic options have been developed based on the conjugation of drugs with polymeric matrices, resulting in nanoparticles or hydrogels with improved properties. Some antineoplastic drugs have been conjugated with antibodies to improve their selectivity and specificity. One of the most important advances in the treatment of breast cancer has been the development of cyclin inhibitors and gene therapy. This review provides an overview of drugs derived from medicinal plants and polymeric matrices with high potential for use in the treatment of breast cancer. We also highlight the clinical evidence for the use of anti-HER2 monoclonal antibodies and cyclin inhibitors in breast cancer, as well as the advantages of using conjugated antibodies. Finally, we mention some considerations that should be taken into account in the search for new therapeutic agents from phytochemicals, polymers, antibodies, cyclin inhibitors, and gene therapy focused on the treatment of breast cancer.","PeriodicalId":12592,"journal":{"name":"Future Pharmacology","volume":"52 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135251308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Antioxidant Potential and Known Secondary Metabolites of Rare or Underutilized Plants of Yucatan Region 尤卡坦地区稀有或未充分利用植物的抗氧化潜能和已知次生代谢物

Future Pharmacology Pub Date : 2023-10-07 DOI: 10.3390/futurepharmacol3040042

Jonatan Jafet Uuh-Narvaez, Maira Rubi Segura-Campos, Oksana Sytar

{"title":"Antioxidant Potential and Known Secondary Metabolites of Rare or Underutilized Plants of Yucatan Region","authors":"Jonatan Jafet Uuh-Narvaez, Maira Rubi Segura-Campos, Oksana Sytar","doi":"10.3390/futurepharmacol3040042","DOIUrl":"https://doi.org/10.3390/futurepharmacol3040042","url":null,"abstract":"The screening of rare plants from the Yucatan region and the known native plants in Mexico, that have been successfully introduced worldwide, has been conducted. Based on a literature analysis and a search of English and Spanish scientific information regarding botanical, plant biochemical, and antioxidant potential in databases such as Google Scholar, Scopus, Web of Knowledge, as well as the national databases of Mexico (Flora: Yucatan Peninsula (cicy.mx) and Especies endémicas|Biodiversidad Mexicana), rare or underutilized plants from the Yucatan region with antioxidant potential have been selected. The formulas of the most studied secondary metabolites of these selected rare plants are shown. Among the selected rare plants with antioxidant potential, the families Sapidaceae and Anacardiaceae had the highest number of representatives. Additionally, representatives from the families Annonaceae, Moraceae, Malpighiaceae, Solanaceae, Ebenaceae, Asteraceae, Ranunculaceae, and Leguminosae were also presented. The current scientific data analysis of selected rare plants from the Yucatan region, Mexico, provides significant background for their further use and introduction in not only the Yucatan region of Mexico, but also worldwide.","PeriodicalId":12592,"journal":{"name":"Future Pharmacology","volume":"298 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135301744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Moles of Molecules against Mycobacterium abscessus: A Review of Current Research 抗脓肿分枝杆菌分子的研究进展

Future Pharmacology Pub Date : 2023-09-11 DOI: 10.3390/futurepharmacol3030041

Mario Cocorullo, Christian Bettoni, Sara Foiadelli, Giovanni Stelitano

引用次数: 0

Aurones as Antidiabetic Agents and Their Prebiotic Activities Aurones作为抗糖尿病药物及其益生元活性

Future Pharmacology Pub Date : 2023-09-07 DOI: 10.3390/futurepharmacol3030040

Reham M. Samra, Mohamed S. Darwish, Noha A. Abou-Zeid, E. Khojah, V. Imieje, A. Zaki

{"title":"Aurones as Antidiabetic Agents and Their Prebiotic Activities","authors":"Reham M. Samra, Mohamed S. Darwish, Noha A. Abou-Zeid, E. Khojah, V. Imieje, A. Zaki","doi":"10.3390/futurepharmacol3030040","DOIUrl":"https://doi.org/10.3390/futurepharmacol3030040","url":null,"abstract":"Cyperus conglomeratus has been utilized in traditional medicine as an emollient, diuretic, analgesic, anthelmintic, and for other diseases. Furthermore, several biological activities have been reported for the plant extract and the isolated metabolites. The chromatographic investigation of an ethyl acetate extract of the aerial parts led to the isolation of three aurone derivatives (1–3) from the plant for the first time. Their structures were identified as aureusidin (1), aureusidin-4-methyl ether (2), and 5-methyl aureusidin (3) using 1D and 2D NMR techniques, along with mass spectrometry. The compounds were tested for their inhibitory activities against enzymes vital in metabolic diseases, especially diabetes, such as α-amylase, α-glucosidase, and glycogen phosphorylase. The results were expressed as percentage inhibition. The inhibitory activity of aurones against the tested enzymes was also analyzed by computational docking studies to provide a rational explanation for the observed results. The tested compounds formed stable interactions in terms of hydrogen bonding and hydrophobic interaction with the active site residues of the tested enzymes, and the results are in agreement with those of the in vitro antidiabetic activity. The compounds were also evaluated for their ability to support the growth and viability of beneficial bacteria in terms of prebiotic activities using two species, Lacticaseibacillus paracasei and Lacticaseibacillus rhamnosus, through the determination of prebiotic activity scores (Pscore). The findings of this study showed that C. conglomeratus is a potential natural source of bioactive agents. There is, however, a need for in vivo testing to evaluate this plant’s efficacy for developing new drug entities in the future.","PeriodicalId":12592,"journal":{"name":"Future Pharmacology","volume":"456 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77010890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Systemic Inflammasome Biomarkers as Predictors of Diabetic Retinopathy Progression: Evidence from a Pilot Study 系统性炎性体生物标志物作为糖尿病视网膜病变进展的预测因子:来自一项初步研究的证据

Future Pharmacology Pub Date : 2023-09-07 DOI: 10.3390/futurepharmacol3030039

C. Kuo, I. Rupenthal, Michael Booth, Rinki Murphy, Odunayo O. Mugisho

{"title":"Systemic Inflammasome Biomarkers as Predictors of Diabetic Retinopathy Progression: Evidence from a Pilot Study","authors":"C. Kuo, I. Rupenthal, Michael Booth, Rinki Murphy, Odunayo O. Mugisho","doi":"10.3390/futurepharmacol3030039","DOIUrl":"https://doi.org/10.3390/futurepharmacol3030039","url":null,"abstract":"The nucleotide-binding oligomerization domain (NOD)-like receptor (NLR) protein 3 (NLRP3) inflammasome pathway is believed to mediate chronic inflammation in diabetic retinopathy (DR); however, its impact on the progression of DR remains to be elucidated. Therefore, the primary aim of this pilot study was to determine whether systemic inflammasome biomarkers interleukin (IL)-1β and IL-18 can be used to predict DR progression. DR screening results were analyzed against weight, level of glycated hemoglobin (HbA1c), and plasma levels of inflammasome biomarkers (IL-1β and IL-18), as well as general inflammation markers (C-reactive protein (CRP), IL-6, IL-8, tumor necrosis factor-alpha (TNF-α), and vascular endothelial growth factor (VEGF)) in patients with type 2 diabetes at baseline and 1 year post-bariatric surgery. Cross-sectional analysis demonstrated that weight, HbA1c, CRP, and IL-18 did not correlate with DR severity. The progressed group showed a higher relative change in IL-18 and CRP levels compared to the stable and regressed groups. Furthermore, relative changes in plasma CRP levels correlated with those of IL-18. Although further validation with larger cohorts is necessary, this pilot study supports the hypothesis that systemic inflammasome activation is associated with DR progression.","PeriodicalId":12592,"journal":{"name":"Future Pharmacology","volume":"45 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88293244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cyclodextrin in Vaccines: Enhancing Efficacy and Stability 环糊精在疫苗中的应用:增强效力和稳定性

Future Pharmacology Pub Date : 2023-08-24 DOI: 10.3390/futurepharmacol3030038

Gamze Varan

{"title":"Cyclodextrin in Vaccines: Enhancing Efficacy and Stability","authors":"Gamze Varan","doi":"10.3390/futurepharmacol3030038","DOIUrl":"https://doi.org/10.3390/futurepharmacol3030038","url":null,"abstract":"Cyclodextrins, a family of cyclic oligosaccharides, have received considerable interest in the field of pharmaceuticals due to their unique molecular structure and versatile properties. In the context of vaccines, cyclodextrins can effectively encapsulate antigens, ensuring their protection from degradation and improving their immunogenicity. Cyclodextrins offer stability advantages to vaccines by preventing the degradation of labile vaccine components during storage and transportation. Furthermore, cyclodextrins can serve as adjuvants, potentiating the immune response triggered by vaccines. Their unique structure and interaction with the immune system enhance the recognition of antigens by immune cells, leading to an improved activation of both innate and adaptive immune responses. This adjuvant effect contributes to the development of robust and long-lasting immune protection against targeted pathogens. Owing to the distinctive attributes inherent to nanoparticles, their integration into vaccine formulations has assumed an imperative role. Through the encapsulation of vaccine antigens/adjuvants within cyclodextrin nanoparticles, the potency and stability of vaccines can be notably enhanced. In particular, the capacity of amphiphilic cyclodextrins to form nanoparticles through self-assembly without surfactants or co-solvents is a captivating prospect for their application as carrier systems for antigens. In conclusion, cyclodextrins present a promising platform for enhancing the efficacy and stability of vaccines. Their ability to encapsulate antigens, stabilize labile vaccine components and act as adjuvants demonstrates their potential to revolutionize vaccine formulation and delivery. Further research and development in this field will facilitate the translation of cyclodextrin-based vaccine technologies into practical and impactful immunization strategies, ultimately benefiting global health and disease prevention.","PeriodicalId":12592,"journal":{"name":"Future Pharmacology","volume":"13 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87763651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Preferred Therapy for Patients with Hereditary Angioedema during Pregnancy 妊娠期遗传性血管性水肿患者的首选治疗方法

Future Pharmacology Pub Date : 2023-08-11 DOI: 10.3390/futurepharmacol3030037

K. Park, A. Yeich, T. Craig

引用次数: 0

Correction: de Almeida et al. Acute Promyelocytic Leukemia (APL): A Review of the Classic and Emerging Target Therapies towards Molecular Heterogeneity. Future Pharmacol. 2023, 3, 162–179 更正:de Almeida等人。急性早幼粒细胞白血病(APL):经典和新兴靶向治疗分子异质性的综述。中国药理学杂志，2016,32 (3):662 - 669

Future Pharmacology Pub Date : 2023-08-04 DOI: 10.3390/futurepharmacol3030036

Tâmara Dauare de Almeida, F. Evangelista, A. Sabino

引用次数: 0

Design of a Cyclodextrin Bioproduction Process Using Bacillus pseudofirmus and Paenibacillus macerans 假硬芽孢杆菌和芽胞杆菌生产环糊精的工艺设计

Future Pharmacology Pub Date : 2023-07-11 DOI: 10.3390/futurepharmacol3030035

Alexandre Miguel Guedes, Tiago Filipe Santos Alves, P. Salústio, H. Cabral-Marques, M. Ribeiro

{"title":"Design of a Cyclodextrin Bioproduction Process Using Bacillus pseudofirmus and Paenibacillus macerans","authors":"Alexandre Miguel Guedes, Tiago Filipe Santos Alves, P. Salústio, H. Cabral-Marques, M. Ribeiro","doi":"10.3390/futurepharmacol3030035","DOIUrl":"https://doi.org/10.3390/futurepharmacol3030035","url":null,"abstract":"Cyclodextrin (CD) drug delivery systems offer the potential to enhance the desired physicochemical properties and pharmacokinetic parameters of drugs while maintaining their safety. Cyclodextrin-glucosyl-transferase (CGTase) is amongst the most important enzymes used in CD biosynthesis. However, the bioproduction of CDs still faces challenges in terms of optimization and process complexity. This study proposes a novel CD bioproduction system in a batch mode to increase yield and reduce costs. Two bacterial strains were selected: the alkalophilic Bacillus pseudofirmus DSM2517 strain and the neutrophilic Paenibacillus macerans DSM1574 strain. Three different culture media, two temperatures (30 °C and 37 °C), and three scales (shake flasks 20 mL and 100 mL, and bioreactor 3.2 L) were evaluated with respect to bacterial growth kinetics, protein production, and CGTase biosynthesis and activity for β-CD production. Bacterial growth was monitored by measuring optical density (OD600 nm), while CGTase activity was assessed by measuring β-CD production directly in the medium after filtration or in samples after concentration (using a Vivaspin 500® ultrafiltration spin column with a 10 kDa cut-off). β-CD quantification was performed using the phenolphthalein colorimetric method and HPLC. The best conditions for combined growth and protein production, for both microorganisms, in shake flasks were achieved with a medium containing 2% dextrin as the carbohydrate source. Scale-up to the bioreactor displayed improved growth kinetics for both bacteria and higher protein production and CGTase activity for Paenibacillus macerans.","PeriodicalId":12592,"journal":{"name":"Future Pharmacology","volume":"25 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90788856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Use of Plant Extracts, Bee-Derived Products, and Probiotic-Related Applications to Fight Multidrug-Resistant Pathogens in the Post-Antibiotic Era 后抗生素时代，植物提取物、蜜蜂衍生产品和益生菌在对抗多重耐药病原体中的应用

Future Pharmacology Pub Date : 2023-07-04 DOI: 10.3390/futurepharmacol3030034

André G. Machado, Lizbeth Zamora-Mendoza, F. Alexis, J. M. Álvarez-Suarez

{"title":"Use of Plant Extracts, Bee-Derived Products, and Probiotic-Related Applications to Fight Multidrug-Resistant Pathogens in the Post-Antibiotic Era","authors":"André G. Machado, Lizbeth Zamora-Mendoza, F. Alexis, J. M. Álvarez-Suarez","doi":"10.3390/futurepharmacol3030034","DOIUrl":"https://doi.org/10.3390/futurepharmacol3030034","url":null,"abstract":"The ‘post-antibiotic’ era is near according to the World Health Organization (WHO). It is well known, due to the work of the scientific community, that drugs (antibiotics, antifungals, and other antimicrobial agents) are continuously becoming less effective, and multidrug-resistant (MDR) pathogens are on the rise. This scenario raises concerns of an impending global infectious disease crisis, wherein a simple opportunistic infection could be deadly for humans. The war against MDR pathogens requires innovation and a multidisciplinary approach. The present study provides comprehensive coverage of relevant topics concerning new antimicrobial drugs; it suggests that a combination of different natural products (such as plant extracts, honey, propolis, prebiotics, probiotics, synbiotics, and postbiotics), together with drug therapy, could be used as an adjuvant in standard treatments, thus allowing drug sensitivity in MDR pathogens to be restored, host immunity to be enhanced, and clinical efficiency to be improved. Currently, new and relevant developments in genomics, transcriptomics, and proteomics are available for research, which could lead to the discovery of new antimicrobial drugs and a new generation of antibiotics and non-antibiotics. However, several areas concerning natural products and their combination with standard drugs remain unclear. In an effort to advance new therapies for humankind, these gaps in the literature need to be addressed.","PeriodicalId":12592,"journal":{"name":"Future Pharmacology","volume":"4 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82152706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0